ID   Mahlavu
AC   CVCL_0405
SY   MAHLAVU
DR   BTO; BTO:0004471
DR   MCCL; MCC:0000299
DR   cancercelllines; CVCL_0405
DR   ChEMBL-Cells; CHEMBL4295417
DR   ChEMBL-Targets; CHEMBL4296473
DR   CLS; 300473
DR   Cosmic; 873398
DR   Cosmic; 948064
DR   Cosmic; 979727
DR   Cosmic; 1019317
DR   Cosmic; 2162534
DR   Cosmic; 2321039
DR   GEO; GSM2551578
DR   IARC_TP53; 2183
DR   LIMORE; Mahlavu
DR   PubChem_Cell_line; CVCL_0405
DR   Wikidata; Q54903975
RX   CelloPub=CLPUB00076;
RX   CelloPub=CLPUB00575;
RX   DOI=10.1007/978-4-431-68349-0_4;
RX   PubMed=179808;
RX   PubMed=2439335;
RX   PubMed=6268737;
RX   PubMed=6275024;
RX   PubMed=8050184;
RX   PubMed=8224613;
RX   PubMed=23887712;
RX   PubMed=25574106;
RX   PubMed=31063779;
RX   PubMed=31378681;
WW   https://lccl.zucmanlab.com/hcc/cellLines/Mahlavu
CC   Part of: Liver Cancer Model Repository (LIMORE).
CC   Population: African.
CC   Doubling time: 22.5 hours (CelloPub=CLPUB00076); 52.01 hours (PubMed=31378681).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Ile391Met (c.1173A>G); ClinVar=VCV000135038; Zygosity=Unspecified (PubMed=31378681).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>T); ClinVar=VCV000012352; Zygosity=Unspecified (PubMed=8224613; PubMed=31063779).
CC   Omics: Deep exome analysis.
CC   Omics: Genome sequenced.
CC   Omics: miRNA expression profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Misspelling: Malhavu; Note=Occasionally.
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
ST   Source(s): CLS; PubMed=31378681
ST   Amelogenin: X
ST   CSF1PO: 7,11
ST   D12S391: 18
ST   D13S317: 12,13
ST   D16S539: 11
ST   D18S51: 15
ST   D19S433: 11,14
ST   D21S11: 31.2,32.2
ST   D2S1338: 19,22
ST   D3S1358: 17
ST   D5S818: 12
ST   D6S1043: 12
ST   D7S820: 10,11
ST   D8S1179: 11,14
ST   FGA: 28
ST   Penta D: 9,11
ST   Penta E: 8,11
ST   TH01: 7
ST   TPOX: 8,10
ST   vWA: 15
DI   NCIt; C3099; Hepatocellular carcinoma
DI   ORDO; Orphanet_88673; Hepatocellular carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 24
//
RX   CelloPub=CLPUB00076;
RA   Prozesky O.W., Brits C., Grabow W.O.K.;
RT   "In vitro culture of cell lines from Australia antigen positive and
RT   negative hepatoma patients.";
RL   (In) Liver; Saunders S.J., Terblanche J. (eds.); pp.358-360; Pitman Medical Books; London (1973).
//
RX   CelloPub=CLPUB00575;
RA   Prozesky O.W., Lecatsas G.;
RT   "Scanning electron microscopy of a human hepatoma cell line.";
RL   S. Afr. Med. J. 49:1061-1062(1975).
//
RX   DOI=10.1007/978-4-431-68349-0_4;
RA   Alexander J.J.;
RT   "Human hepatoma cell lines.";
RL   (In) Neoplasms of the liver; Okuda K., Ishak K.G. (eds.); pp.47-56; Springer; Tokyo (1987).
//
RX   PubMed=179808; DOI=10.1111/j.1432-1033.1976.tb10294.x;
RA   Grimm J.;
RT   "The influence of insulin on various enzyme activities in human and
RT   rat hepatoma cells.";
RL   Eur. J. Biochem. 64:249-253(1976).
//
RX   PubMed=2439335; DOI=10.1111/j.1432-1033.1987.tb11497.x;
RA   Vincent C., Marceau M., Blangarin P., Bouic P., Madjar J.-J.,
RA   Revillard J.-P.;
RT   "Purification of alpha 1-microglobulin produced by human hepatoma cell
RT   lines. Biochemical characterization and comparison with alpha
RT   1-microglobulin synthesized by human hepatocytes.";
RL   Eur. J. Biochem. 165:699-704(1987).
//
RX   PubMed=6268737; DOI=10.1099/0022-1317-53-1-105;
RA   Oefinger P.E., Bronson D.L., Dreesman G.R.;
RT   "Induction of hepatitis B surface antigen in human hepatoma-derived
RT   cell lines.";
RL   J. Gen. Virol. 53:105-113(1981).
//
RX   PubMed=6275024; DOI=10.1099/0022-1317-57-1-95;
RA   Koshy R., Maupas P., Muller R., Hofschneider P.H.;
RT   "Detection of hepatitis B virus-specific DNA in the genomes of human
RT   hepatocellular carcinoma and liver cirrhosis tissues.";
RL   J. Gen. Virol. 57:95-102(1981).
//
RX   PubMed=8050184; DOI=10.1111/j.1365-2249.1994.tb06089.x;
RA   Wadee A.A., Paterson A., Coplan K.A., Reddy S.G.;
RT   "HLA expression in hepatocellular carcinoma cell lines.";
RL   Clin. Exp. Immunol. 97:328-333(1994).
//
RX   PubMed=8224613; DOI=10.1096/fasebj.7.14.8224613;
RA   Puisieux A., Galvin K., Troalen F., Bressac B., Marcais C., Galun E.,
RA   Ponchel F., Yakicier C., Ji J.-W., Ozturk M.;
RT   "Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell
RT   lines.";
RL   FASEB J. 7:1407-1413(1993).
//
RX   PubMed=23887712; DOI=10.1038/ncomms3218;
RA   Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P.,
RA   Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.;
RT   "High frequency of telomerase reverse-transcriptase promoter somatic
RT   mutations in hepatocellular carcinoma and preneoplastic lesions.";
RL   Nat. Commun. 4:2218.1-2218.7(2013).
//
RX   PubMed=25574106; DOI=10.3748/wjg.v21.i1.311;
RA   Cevik D., Yildiz G., Ozturk M.;
RT   "Common telomerase reverse transcriptase promoter mutations in
RT   hepatocellular carcinomas from different geographical locations.";
RL   World J. Gastroenterol. 21:311-317(2015).
//
RX   PubMed=31063779; DOI=10.1053/j.gastro.2019.05.001;
RA   Caruso S., Calatayud A.-L., Pilet J., La Bella T., Rekik S.,
RA   Imbeaud S., Letouze E., Meunier L., Bayard Q., Rohr-Udilova N.,
RA   Peneau C., Grasl-Kraupp B., de Koning L., Ouine B., Bioulac-Sage P.,
RA   Couchy G., Calderaro J., Nault J.-C., Zucman-Rossi J., Rebouissou S.;
RT   "Analysis of liver cancer cell lines identifies agents with likely
RT   efficacy against hepatocellular carcinoma and markers of response.";
RL   Gastroenterology 157:760-776(2019).
//
RX   PubMed=31378681; DOI=10.1016/j.ccell.2019.07.001;
RA   Qiu Z.-X., Li H., Zhang Z.-T., Zhu Z.-F., He S., Wang X.-J.,
RA   Wang P.-C., Qin J.-J., Zhuang L.-P., Wang W., Xie F.-B., Gu Y.,
RA   Zou K.-K., Li C., Li C., Wang C.-H., Cen J., Chen X.-T., Shu Y.-J.,
RA   Zhang Z., Sun L.-L., Min L.-H., Fu Y., Huang X.-W., Lv H., Zhou H.,
RA   Ji Y., Zhang Z.-G., Meng Z.-Q., Shi X.-L., Zhang H.-B., Li Y.-X.,
RA   Hui L.-J.;
RT   "A pharmacogenomic landscape in human liver cancers.";
RL   Cancer Cell 36:179-193.e11(2019).
//